Clinical Experience of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
|
|
- Colin Hill
- 6 years ago
- Views:
Transcription
1 Clinical Experience of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia STEVEN L. SOIGNET Memorial Sloan-Kettering Cancer Center and Department of Medicine, and the Joan and Sanford Weill Medical College of Cornell University, New York, New York, USA Key Words. Acute promyelocytic leukemia Arsenic trioxide All-trans retinoic acid Chemotherapy ABSTRACT Acute promyelocytic leukemia (APL) has unique clinical, cytogenetic, and molecular features and is one of the most potentially curable human malignancies. The current standard treatment given to patients with newly diagnosed APL con-sists of all-trans retinoic acid and anthracycline-based cytotoxic chemotherapy, which is highly effective for remission induction. However, despite the potential for cure with existing treatments, approximately 20%-30% of patients relapse and require salvage therapy. Reports of the safety and efficacy of arsenic trioxide from centers in China led to a pivotal trial of this agent in the United States for patients with relapsed APL. In an initial pilot study, 11 of 12 patients experienced a complete response, and a subsequent multicenter trial confirmed the efficacy and safety of arsenic trioxide for remission induction in this patient population. Additional trials are under way to evaluate the use of this agent alone or as part of a chemotherapy regimen for consolidation and maintenance of patients with APL. The Oncologist 2001;6(suppl 2):11-16 INTRODUCTION Acute promyelocytic leukemia ([APL] French American and British [FAB] M3) is a distinctive type of acute myelogenous leukemia and represents approximately 10%-15% of adult myeloid leukemias [1]. The annual incidence of newly diagnosed APL in the United States is approximately 1,000 to 1,500 cases; another 2,500 to 4,000 cases occur outside the United States. Although relatively uncommon, APL has been the subject of intensive interest because of its distinctive clinical, morphologic, cytogenetic, and molecular properties. First recognized as a distinct clinical entity in the 1950s, APL is characterized by a severe coagulopathy, high early mortality, and peripheral blood and bone marrow dominated by abnormal heavily granulated promyelocytes [2]. The bleeding diathesis of APL is associated with a high potential for early hemorrhagic death and is present in the majority of these patients at the time of their initial diagnosis requiring aggressive management with platelet and fresh/frozen plasma transfusions [3]. Multifactorial in etiology, the bleeding propensity is caused by a combination of disseminated intravascular coagulation and hyperfibrinolysis [4]. Induction therapy with cytotoxic chemotherapy can precipitate or exacerbate the coagulopathy, because lysis of the hypergranular leukemic promyelocytes releases their content (tissue factor and procoagulants) into the plasma, resulting in the consumption of the clotting factors. Fibrinolysis may be caused by increased expression by the leukemic cells of annexin II, a receptor for fibrinolytic proteins, and decreased activity of thrombin-activatable fibrinolysis inhibitor [4, 5]. Before the early 1990s, therapy for APL consisted of an anthracycline antibiotic plus cytosine arabinoside for induction, followed by additional cycles of chemotherapy for consolidation and/or maintenance [6]. This standard approach resulted in complete remissions (CRs) in 60%- 80% of patients; 5-year survival rates were 20%-30% [6]. Since the incorporation of all-trans retinoic acid (ATRA) into the treatment regimen in the early 1990s, the overall and disease-free survival of patients with APL has increased by nearly twofold, in addition to an increased CR rate [1, 6]. However, 20%-30% of patients with APL relapse despite this advancement [7]. Salvage therapy for these patients entailed high doses of cytotoxic chemotherapy, treatment that is often toxic and rarely curative. Bone marrow transplantation, although potentially curative, is an Correspondence: Steven L. Soignet, M.D., Developmental Chemotherapy Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York , USA. Telephone ; Fax ; soignets@mskcc.org Received March 23, 2001; accepted for publication March 24, AlphaMed Press /01/$5.00/0 The Oncologist 2001;6(suppl2):
2 12 Clinical Experience with Arsenic Trioxide in APL option for only a fraction of the younger relapsed patients. An initial pilot study and a subsequent confirmatory multicenter trial of arsenic trioxide (Trisenox TM ) in patients with relapsed APL demonstrated a high rate of CRs that included molecular remissions in over half the patients after receiving one to two cycles of therapy. This article discusses the background, evaluation, and clinical utility of the use of this agent in patients with APL. CYTOGENETIC FEATURES AND MOLECULAR PATHOGENESIS OF APL In the 1970s, patients with APL were found to have a balanced and reciprocal translocation involving the long arms of chromosomes 15 and 17 [t(15;17)(q22;q21)] [8]. This translocation is virtually diagnostic for this subtype of acute myelogenous leukemia. At a molecular level, this cytogenetic abnormality reflects disruption of the promyelocytic leukemia gene (PML) on chromosome 15 and the retinoic acid receptorα gene (RAR-α) on chromosome 17 [9-11]. The resultant fusion gene, t(15;17), encodes the chimeric proteins PML/RAR-α and RAR-α/PML. The former is found in nearly all patients with the t(15;17) trans-location, whereas the latter is detected in about two-thirds of patients [12]. Small numbers of patients with clinical APL lack this specific cytogenetic abnormality. In these rare cases in which no PML involvement can be found, the RAR-α gene is linked to the promyelocytic leukemia zinc finger on chromosome 11, nucleophosmin on chromosome 5, or the nuclear mitotic apparatus protein gene on chromosome 11 [13]. In addition to their well-known effects on vision, retinoids are prime regulators of cell proliferation and differentiation and have a critical role in embryonic morphogenesis [12]. Two families of retinoic acid receptors, each with three subtypes, RAR-α, -β, -γ, and RXR-α, -β, -γ, regulate transcription of target genes [14]. Only the RARs are activated by complexing with retinoic acid. The RAR-α translocation plays a strong role in the pathogenesis in APL, by interfering with the physiological activity of the normal RAR-α protein and exerting a dominant negative effect [9, 15]. As a result, the fusion protein disrupts direct transcriptional control of certain primary target genes, interferes with other transcriptional factors, and exerts post-transcriptional effects such as the induction of transforming growth factor β [16]. Ultimately myeloid differentiation is inhibited, leading to the accumulation of the leukemic cells at the promyelocytic stage of development. CURRENT THERAPEUTIC APPROACHES IN THE MANAGEMENT OF APL Since the introduction of ATRA into the upfront APL treatment regimen, CR rates as well as disease-free survival have improved significantly. However, newer therapies are needed for patients who fail to respond or who relapse after treatment with current standard therapy. ATRA-BASED THERAPY Role of Retinoids in APL Therapy In 1978, Sachs reported that cells from a murine leukemic cell line could be induced from an immature to a mature phenotype [17]. Subsequently, Breitman et al. found that exposure to ATRA could induce differentiation in HL- 60 cells, a cell line with elements resembling leukemic promyelocytes but lacking t(15;17) [18]. In the latter part of the 1980s, treatment of APL was revolutionized when Chinese investigators reported that a high proportion of patients treated with capsules of ATRA achieved CRs [19]. The success of ATRA is believed to be due to its ability to induce differentiation of the leukemic clone. Pharmacologic doses of ATRA degrade the aberrant fusion protein, thereby overcoming the dominant negative effect of PML/RAR-α fusion proteins [15]. ATRA as Single-Agent Therapy Clinical trials of single-agent ATRA have reported CR rates ranging between 50%-80% a rate comparable to that achieved with standard cytotoxic chemotherapy [20]. Patients treated with this approach would be expected to undergo remission without an interval of aplasia or a worsening of the coagulopathy seen with standard chemotherapy. However, the duration of remission in patients treated with ATRA alone has been relatively brief, and essentially all patients relapse within 10 months [21]. Therefore, ATRA is administered as a standard component of combination chemotherapy with an anthracycline antibiotic in patients with APL [22]. Chronology of ATRA Administration Although the inclusion of ATRA with standard chemotherapy appeared likely to improve outcomes, the optimal schedule of administration of the two treatments was unclear. Several studies were conducted to determine the optimal ATRA/chemotherapy induction regimen in patients with APL [6, 23-26]. In a large randomized trial comparing sequential versus concurrent ATRA and chemotherapy, CR occurred in 381 patients (92%), with similar proportions of patients in both treatment groups experiencing CR. At 2 years follow-up, significantly more patients in the sequential group than in the concurrent group had relapsed (16% versus 6%; p = 0.04). Also, the addition of chemotherapy to ATRA at the initiation of treatment led to CR rates higher than 90%. Furthermore, recent trials
3 Soignet 13 have shown a benefit for maintenance therapy with ATRA, with or without low-dose chemotherapy, suggesting it be indicated for all patients with APL [27]. ATRA Plus Chemotherapy Followed by Hematopoietic Stem Cell Transplantation as Salvage Therapy The optimum postremission therapy for patients with APL has not yet been defined. For the approximately 20%- 30% of patients who relapse, treatment with ATRA and/or chemotherapy can usually produce a second CR, but stem cell transplantation may provide greater benefit. This approach was tested in a population of patients who relapsed and achieved a second CR with ATRA followed by timed etoposide/mitoxantrone/cytosine arabinoside therapy [28]. After CR, patients underwent myeloablation followed by either autologous or allogeneic (HLA-compatible donor and < 55 years of age) transplant. Although the combination of ATRA and etoposide/mitoxantrone/cytosine arabinoside was effective in the treatment of relapsed APL, allogeneic transplantation in this setting was associated with significant toxicity and high mortality. However, the results of autografting were encouraging, with a 3-year disease-free survival of 77%. ARSENIC TRIOXIDE-BASED THERAPY Role of Arsenicals in Leukemia Therapy Since ancient Greek and Roman civilizations, arsenic has been an active ingredient in the folk remedies of central and southern Asia [29]. In 1878, a formulation of arsenic (Fowler s solution) was first used to treat leukemia [30]. In 1992, Sun et al. in China described 32 cases of morphologic APL (not confirmed by cytogenetics or reverse transcriptase polymerase chain reaction [RT-PCR]) treated with Ailing-1, a Chinese herbal arsenical preparation [31]. Of the initial cases, 16 of 32 (50%) survived more than 5 years without any anthracycline-based therapy. This and other studies from China stimulated intensive investigation on the role of arsenic trioxide in the treatment of APL and other malignancies [32-34]. The mechanisms behind the effects of arsenic therapy for APL are not completely understood. Studies on APLderived cell lines and transgenic mice carrying the PML/RARα fusion proteins indicate that arsenic trioxide induces degradation of both the chimeric PML/RAR-α and native PML from the nuclei of the malignant cells [35, 36]. This allows partial differentiation of the leukemic population to proceed [36]. Arsenic trioxide also induces apoptosis possibly by indirectly impairing H 2 O 2 catabolism with a resultant decrease in mitochondrial membrane potential, release of cytochrome c, and activation and upregulation of caspases 1, 2, 3, and 8, [1, 37, 38]. Arsenic Trioxide in Relapsed and Refractory Patients After the Chinese reports of the efficacy of arsenic trioxide in APL, in 1997 a pilot study of this compound was initiated in 12 relapsed patients (Table 1) [1]. Of the 12 Table 1. Clinical characteristics and results of therapy with arsenic trioxide Patient Age (y) Relapses Duration of Daily dose Cumulative Time to therapy (d) (mg/kg/d) dose (mg) remission (d) * * * * * * * * Retinoid resistant. Treated with chemotherapy: patients 2, 3, and 8 (mitoxantrone and etoposide) and patient 10 (methotrexate, vincristine, and mercaptopurine). Previously treated with allogeneic bone marrow transplantation. Also treated with 9-cis-retinoic acid plus a monoclonal antibody to CD33. Died of an intracerebral hemorrhage on day 5. Modified with permission [1].
4 14 Clinical Experience with Arsenic Trioxide in APL patients, 11 (92%) had a CR after treatment ranging from 12 to 39 days (median, 33 days). Median daily dose was approximately 0.16 mg/kg (range, mg/kg), and the median cumulative dose was 360 mg (range, mg); this dosage was similar to that reported by the Chinese investigators. In addition to the high CR rate, 8 of the 11 patients who initially tested positive for PML/RAR-α by RT-PCR later became negative. The above results were supported and extended by follow-up from the U.S. pilot and multicenter trials [39]. Combining the results from the pilot and multicenter studies, the CR rate was 87% (45 of 52), with a molecular conversion rate from positive to negative for the PML/RAR-α transcript of 78% [40]. Of the 45 patients achieving a CR, 31 (69%) remained alive at a median follow-up of 18 months. Adverse events reported with arsenic trioxide include leukocytosis, the APL differentiation syndrome, QT prolongation on electrocardiogram, peripheral neuropathy, hyperglycemia, and skin reactions. The APL differentiation syndrome, which is clinically identical to the previously named retinoic acid syndrome, was observed in approximately 30% of the APL patients treated with arsenic trioxide for remission induction. The syndrome consists of one or more of the following signs or symptoms: fevers, skin rash, peripheral edema, pulmonary infiltrates, and plural or pericardial effusions [41]. This syndrome is effectively treated with dexamethasone if treatment is initiated at the first sign or symptom. Asymptomatic QT prolongation on electrocardiogram was seen in over half the patients treated with arsenic trioxide. The management of QT prolongation consisted of maintaining serum potassium levels > 4.0 meq/dl, and magnesium levels > 1.8 mg/dl. If the QTc is >500 msec, corrective actions should be taken, including telemetry monitoring, and the risk/benefits of continuing therapy should be considered. Other adverse events included peripheral neuropathy, lightheadedness during the infusion, fatigue, musculoskeletal pain, and mild hyperglycemia. Toxicities were manageable and similar to those described in the pilot. The investigators concluded that arsenic trioxide is highly effective for clinical and molecular remission induction in patients with relapsed APL. Consequently, patients can be offered additional strategies, including autologous or allogeneic stem cell transplantations and/or consolidation chemotherapy to increase their long-term, disease-free survival. SUMMARY AND CONCLUSIONS The introduction of ATRA has significantly improved the disease-free and overall survival in patients with APL. CR Remission maintained Arsenic trioxide maintenance Induction Therapy: ATRA Plus Anthracyclines Relapsed CR Auto-BMT Refractory Arsenic trioxide Refractory Allo-BMT for eligible patients Figure 1. Treatment options for patients with APL. Current treatment for newly diagnosed acute promyelocytic leukemia (APL) patients includes administration of all-trans retinoic acid (ATRA) for remission induction followed by anthracyclines for consolidation. Relapsed patients receive ATRA, and bone marrow transplantation (BMT) is provided only if an HLA-compatible donor is available. Once patients become refractory to ATRA treatment, BMT is the only available treatment alternative; however, arsenic trioxide has been shown to be effective therapy for relapsed or refractory APL patients and provides an alternative to ATRA. CR = complete remission. Currently, ATRA remains first-line therapy in patients presenting with de novo APL. However, the studies presented herein confirm reports from China of the striking efficacy and safety of arsenic trioxide in the treatment of APL. In addition, patients treated with arsenic trioxide had a high rate of molecular conversion to PML/RAR-α negativity. Arsenic trioxide fulfills an unmet medical need based on its ability to induce CR in patients with relapsed APL. The safety profile of the drug is favorable. Adverse events are uncommon, generally self-limiting, and reversible. Therapy with arsenic trioxide offers the opportunity for a CR and improved survival in patients with refractory/ relapsed APL (Fig. 1). In the future, the role of this compound will be evaluated as both a single agent or in combination with chemotherapy for the consolidation and maintenance treatment of patients with APL.
5 Soignet 15 REFERENCES 1 Soignet SL, Maslak P, Wang Z-G et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339: Hillestad LK. Acute promyelocytic leukemia. Acta Med Scand 1957;159: Fenaux P, Chomienne C, Degos L. Acute promyelocytic leukemia: biology and treatment. Semin Oncol 1997;24: Menell JS, Cesarman GM, Jacovina AT et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999;340: Meijers JC, Oudijk EJ, Mosnier LO et al. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 2000; 108: Soignet S, Fleischauer A, Polyak T et al. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemother Pharmacol 1997;40(suppl):S25-S29. 7 Fenaux P, Chevret S, Guerci A et al. Long-term followup confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. Leukemia 2000;14: Rowley JD, Golomb HM, Vardiman J et al. Further evidence for a non-random chromosomal abnormality in acute promyelocytic leukemia. Int J Cancer 1977;20: Kakizuka A, Miller WH Jr, Umesono K et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 1991;66: de Thé H, Chomienne C, Lanotte M et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990;347: Borrow J, Goddard AD, Sheer D et al. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990;249: Warrell RP Jr, de Thé H, Wang Z-Y et al. Acute promyelocytic leukemia. N Engl J Med 1993;329: Grimwade D, Biondi A, Mozziconacci MJ et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Blood 2000;96: Schulman IG, Evans RM. Retinoid receptors in development and disease. Leukemia 1997;11(suppl 3): Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93: Slack JL, Gallagher RE. The molecular biology of acute promyelocytic leukemia. Cancer Treat Res 1999;99: Sachs L. Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia. Nature 1978;274: Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL- 60) by retinoic acid. Proc Natl Acad Sci USA 1980;77: Huang M-E, Ye Y-C, Chen S-R et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72: Tallman MS. Differentiating therapy in acute myeloid leukemia. Leukemia 1996;10: Frankel SR, Eardley A, Heller G et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med 1994;120: Slack JL, Rusiniak ME. Current issues in the management of acute promyelocytic leukemia. Ann Hematol 2000;79: Tallman MS, Andersen JW, Schiffer CA et al. All-transretinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337: Fenaux P, Le Deley MC, Castaigne S et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993;82: Fenaux P, Chastang C, Chevret S et al. A randomized comparison of all-trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999;94: Mandelli F, Diverio D, Avvisati G et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997;90: Slack JL, Rusiniak ME. Current issues in the management of acute promyelocytic leukemia. Ann Hematol 2000;79: Thomas X, Dombret H, Cordonnier C et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. Leukemia 2000;14: Klaassen CD. Heavy metals and heavy-metal antagonists. In: Hardman JG, Gilman AG, Limbird LE, eds. Goodman & Gilman s The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996: Kwong YL, Todd D. Delicious poison: arsenic trioxide for the treatment of leukemia. Blood 1997;89:
6 16 Clinical Experience with Arsenic Trioxide in APL 31 Sun HD, Ma L, Hu X-C et al. Ai-Lin 1 treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chin West Med 1992;12: Shen Z-X, Chen G-Q, Ni J-H et al. Use of arsenic trioxide (As 2 O 3 ) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89: Niu C, Yan H, Yu T et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94: Kroemer G, de Thé H. Arsenic trioxide, a novel mitochondriotoxic anticancer agent? J Natl Cancer Inst 1999;91: Rego EM, He LZ, Warrell RP et al. Retinoic acid (RA) and As 2 O 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci USA 2000;97: Zhu J, Koken MH, Quignon F et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997;94: Jing Y, Dai J, Chalmers-Redman RM et al. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999;94: Kitamura K, Minami Y, Yamamoto K et al. Involvement of CD95-independent caspase 8 activation in arsenic trioxideinduced apoptosis. Leukemia 2000;14: Soignet S, Frankel S, Tallman M et al. U.S. multicenter trial of arsenic trioxide (AT) in acute promyelocytic leukemia (APL). Blood 1999;94(suppl 1):698a. 40 Soignet SL, Frankel S, Tallman M et al. Arsenic trioxide (ATO) in relapsed acute promyelocytic leukemia (APL): the combined results and follow-up from the U.S. pilot and multicenter trials. Blood 2000;96(suppl, pt 1 of 2):827a. 41 Frankel SR, Eardley A, Lauwers G et al. The retinoic acid syndrome in acute promyelocytic leukemia. Ann Intern Med 1992;117:
MOLECULAR AND CLINICAL ONCOLOGY 3: , 2015
MOLECULAR AND CLINICAL ONCOLOGY 3: 449-453, 2015 Evaluation of the efficacy of maintenance therapy for low to intermediate risk acute promyelocytic leukemia in molecular remission: A retrospective single
More informationBelgium recommendations for the management of acute promyelocytic leukaemia
6 Belgium recommendations for the management of acute promyelocytic leukaemia S. Wittnebel, MD, PhD 1 The management of acute promyelocytic leukaemia has evolved considerably. The standard front-line approach
More informationObjectives. I do not have anything to disclose.
Treatment of APL Objectives I do not have anything to disclose. Objectives 1. Urgency of early recognition and treatment 2. Treatment based on risk stratification 3. Monitoring for relapse 4. Treatment
More informationWhich is the best treatment for relapsed APL?
Which is the best treatment for relapsed APL? 7th International Symposium on Acute Promyelocytic Leukemia, Rome, September 24 27, 2017 Eva Lengfelder Department of Hematology and Oncology University Hospital
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationperc deliberated upon: a pcodr systematic review other literature in the Clinical Guidance Report providing clinical context
require close monitoring. perc noted that induction therapy is generally administered in-hospital while consolidation therapy is administered on an out-patient basis. Because of the potential for serious
More informationTreatment of APL. M a tth e w M e i, M.D. A s s is ta n t P ro fe s s o r C ity o f H o p e C o m p re h e n s iv e C a n c e r C e n te r
Treatment of APL M a tth e w M e i, M.D. A s s is ta n t P ro fe s s o r C ity o f H o p e C o m p re h e n s iv e C a n c e r C e n te r Disclosures I have nothing to disclose Objectives 1. Urgency of
More informationTherapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328
Therapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328 Kenneth N. Holder, Leslie J. Greebon, Gopalrao Velagaleti, Hongxin Fan, Russell A. Higgins Initial Case: Clinical
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1997, by the Massachusetts Medical Society VOLUME 337 O CTOBER 9, 1997 NUMBER 15 ALL-TRANS-RETINOIC ACID IN ACUTE PROMYELOCYTIC LEUKEMIA MARTIN S. TALLMAN,
More informationLeukaemia Section Review
Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Leukaemia Section Review t(15;17)(q24;q21) PML/RARA Pino J. Poddighe, Daniel Olde Weghuis Department of Clinical
More informationNew Advances in the Treatment of Acute Promyelocytic Leukemia
HEMATOLOGY New Advances in the Treatment of Acute Promyelocytic Leukemia Dan Douer University of Southern California Keck Scholl of Medicine and Norris Comprehensive Cancer Center, Los Angels, CA, USA
More informationSTATUS OF EARLY MORTALITY IN NEWLY DIAGNOSED CASES OF ACUTE PROMYELOCYTIC LEUKAEMIA (APL) IN BSMMU HOSPITAL
STATUS OF EARLY MORTALITY IN NEWLY DIAGNOSED CASES OF ACUTE PROMYELOCYTIC LEUKAEMIA (APL) IN BSMMU HOSPITAL RAHMAN F 1, YUNUS ABM 2, KABIR AL 3, BEGUM M 4, AZIZ A 3, SHAH S 3, RAHMAN F 5, RAHMAN MJ 6 Abstract:
More informationTen-year Experience on Acute Promyelocytic Leukemia at Inha University Hospital
Korean J Hematol Vol. 41, No. 4, December, 2006 Original Article Ten-year Experience on Acute Promyelocytic Leukemia at Inha University Hospital Hyeon Gyu Yi, M.D., Joo Han Lim, M.D., Jin Soo Kim, M.D.,
More informationAdvances in the Management of Acute Promyelocytic Leukemia and Other Hematologic Malignancies with Arsenic Trioxide
Advances in the Management of Acute Promyelocytic Leukemia and Other Hematologic Malignancies with Arsenic Trioxide JAMES L. SLACK, a SAMUEL WAXMAN, b GUIDO TRICOT, c MARTIN S. TALLMAN, d CLARA D. BLOOMFIELD
More informationPeking University People's Hospital, Peking University Institute of Hematology
Qian Jiang, M.D. Peking University People's Hospital, Peking University Institute of Hematology No. 11 Xizhimen South Street, Beijing, 100044, China. Phone number: 86-10-66583802 Mobile: 86-13611115100
More informationSingle Technology Appraisal (STA) Arsenic trioxide for treating acute promyelocytic leukaemia
Single Technology Appraisal (STA) Arsenic trioxide for treating acute promyelocytic leukaemia Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please note:
More informationPrise en Charge des LAM-3. Hervé Dombret Hôpital Saint-Louis Institut Universitaire d Hématologie Université Paris Diderot
Prise en Charge des LAM-3 Hervé Dombret Hôpital Saint-Louis Institut Universitaire d Hématologie Université Paris Diderot Basal transcription therapy by ATRA h Transcrip onal repression PML RA PML Blast
More informationMatthew Mei, M.D. Assistant t Professor City of Hope Comprehensive Cancer Center
Treatment of APL Matthew Mei, M.D. Assistant t Professor City of Hope Comprehensive Cancer Center Objectives 1. Urgency of early recognition and treatment 2. Treatment based on risk stratification 3. Monitoring
More informationAcute Myeloid Leukemia (AML) Malignant Clone Disorder of Immature Hematopoietic Cells
Acute Myeloid Leukemia (AML) Malignant Clone Disorder of Immature Hematopoietic Cells Ashraf Talaat 1, Nabil Khattab 1, Abdulshafy Tabl 1, Mohamed Samra 2 1 Internal Medicine Department, Faculty of Medicine,
More informationThe Role of ATRA Followed by Chemotherapy in the Treatment of Acute Promyelocytic Leukemia
ORIGINAL ARTICLE The Role of ATRA Followed by Chemotherapy in the Treatment of Acute Promyelocytic Leukemia Hasan Jalaeikhoo 1, Mohsen Rajaeinejad 1, Manoutchehr Keyhani 2, and Mohammad Zokaasadi 1 1 Department
More informationTreatment concepts of acute promyelocytic leukemia
Critical Reviews in Oncology/Hematology 56 (2005) 261 274 Treatment concepts of acute promyelocytic leukemia Eva Lengfelder a,, Susanne Saussele a, Andreas Weisser a, Thomas Büchner b, Rüdiger Hehlmann
More informationClinical commissioning policy statement: Arsenic trioxide for the treatment of high risk acute promyelocytic leukaemia (all ages)
Clinical commissioning policy statement: Arsenic trioxide for the treatment of high risk acute promyelocytic leukaemia (all ages) NHS England Reference: 170072P 1 Contents 1 Plain language summary... 3
More informationA Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults
ABSTRACT The use of all-trans-retinoic acid (atra) and anthracyclines (with or without cytarabine) in the treatment of acute promyelocytic leukemia (apl) has dramatically changed the manment and outcome
More informationBreakthroughs in the treatment of APL: role of arsenic in newlydiagnosed
Breakthroughs in the treatment of APL: role of arsenic in newlydiagnosed patients Jiong Hu, Zhi-Xiang Shen Department of Hematology, RuiJin Hospital, Shanghai JiaoTong Unviersity School of Medicine 1.
More informationAcute Promyelocytic Leukemia: Current Management with Emphasis on Prevention of Induction Mortality
Acute Promyelocytic Leukemia: Current Management with Emphasis on Prevention of Induction Mortality Anand P. Jillella, MD, FACP Professor, Hematology and Medical Oncology Associate Director for Community
More informationAll-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup
More informationAnand P. Jillella, MD; FACP Professor, Hematology and Medical Oncology Associate Director for Community Affairs and Outreach Winship Cancer Institute
Anand P. Jillella, MD; FACP Professor, Hematology and Medical Oncology Associate Director for Community Affairs and Outreach Winship Cancer Institute of Emory University Atlanta, GA 1 Multiple Choice #1
More informationAcute promyelocytic leukemia
Acute promyelocytic leukemia Laura Cicconi University Tor Vergata Rome, Italy Acute Myeloid Leukemia Meeting Ravenna, Italy (October 2017) APL. From highly fatal to curable disease Fatal outcome if not
More informationReference: NHS England 1602
Clinical Commissioning Policy Proposition: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation Reference: NHS England 1602 First published: TBC
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment
More informationAnalysis of factors affecting hemorrhagic diathesis and overall survival in patients with acute promyelocytic leukemia
ORIGINAL ARTICLE Korean J Intern Med 2015;30:884-890 Analysis of factors affecting hemorrhagic diathesis and overall survival in patients with acute promyelocytic leukemia Ho Jin Lee 1, Dong Hyun Kim 1,
More informationMS.4/ 1.Nov/2015. Acute Leukemia: AML. Abdallah Abbadi
MS.4/ 1.Nov/2015. Acute Leukemia: AML Abdallah Abbadi Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising and hemorrhagic spots on her trunk
More informationA Prospective Study on the Effectiveness of Arsenic Trioxide (ATO) in Remission Induction of Acute Promyelocytic Leukemia (APL)
Chattagram Maa-O-Shishu Hospital Medical College Journal Original Article A Prospective Study on the Effectiveness of Arsenic Trioxide (ATO) in Remission Induction of Acute Promyelocytic Leukemia (APL)
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationEffects of Arsenic Trioxide on Electrocardiography
Original Article Acta Cardiol Sin 2004;20:1 6 Electrophysiology Effects of Arsenic Trioxide on Electrocardiography Tu-Ying Liu, 1 Hsiang-Ning Luk, 2 Tsui-Min Wang, 3 Philip Yu-An Ding 1 and Chern-En Chiang
More informationAcute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities
Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities Acute Myeloid Leukemia with recurrent cytogenetic Abnormalities -t(8;21)(q22;q22)(aml/eto) -inv(16) or t(16;16) -t(15;17) -11q23 Acute Myeloid
More informationAcute Promyelocytic Leukemia with i(17)(q10)
CASE REPORT Acute Promyelocytic Leukemia with i(17)(q10) Junki Inamura 1, Katsuya Ikuta 2, Nodoka Tsukada 1, Takaaki Hosoki 1, Motohiro Shindo 2 and Kazuya Sato 1 Abstract We herein report a rare chromosomal
More informationCharacteristics and Outcome of Therapy-Related Acute Promyelocytic Leukemia After Different Front-line Therapies
Characteristics and Outcome of Therapy-Related Acute Promyelocytic Leukemia After Different Front-line Therapies Sabine Kayser, * Julia Krzykalla, Michelle A. Elliott, Kelly Norsworthy, Patrick Gonzales,
More information7th International Symposium on Acute Promyelocytic Leukemia, Rome, September 24 27, Eva Lengfelder
Frontline therapy of acute promyelocytic leukemia: randomized comparison of ATRA and intensified chemotherapy including high dose cytosine-arabinoside versus ATRA and anthracyclines - A prospective multicenter
More informationMS.4/ Acute Leukemia: AML. Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD
MS.4/ 27.02.2019 Acute Leukemia: AML Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising
More informationOncogenes. Dr. S Hosseini-Asl
Oncogenes Dr. S Hosseini-Asl An oncogene is a mutated form of a normal cellular gene called a proto-oncogene that contributes to the development of a cancer. Proto-oncogenes typically regulate cell growth
More informationRemission induction in acute myeloid leukemia
Int J Hematol (2012) 96:164 170 DOI 10.1007/s12185-012-1121-y PROGRESS IN HEMATOLOGY How to improve the outcome of adult acute myeloid leukemia? Remission induction in acute myeloid leukemia Eytan M. Stein
More informationCorrespondence should be addressed to Chen Xue-Liang; chenxl and Hou Ming; houming
Evidence-Based Complementary and Alternative Medicine, Article ID 987560, 7 pages http://dx.doi.org/10.1155/2014/987560 Research Article Clinical Study on Prospective Efficacy of All-Trans Acid, Realgar-Indigo
More informationTRANSPARENCY COMMITTEE OPINION. 14 February 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 February 2007 GLIVEC 100 mg, capsule B/120 capsules (CIP: 358 493-5) GLIVEC 100 mg, capsule B/180 capsules (CIP:
More informationTreatment of acute myeloid leukemia (AML): Recent results and new directions Thomas Büchner University of Münster, Germany
Treatment of acute myeloid leukemia (AML): Recent results and new directions Thomas Büchner University of Münster, Germany Acute myeloid leukemia (AML) is a major indication for hematopoietic stem cell
More informationATRA (ALLTransretinoic acid) drug in treatment of APL (Acute promylocytic leukemia) Mouroge H. Al-Ani Jaffer M. Al-Gabban, Suzan Mahmood MD
ATRA (ALLTransretinoic acid) drug in treatment of APL (Acute promylocytic leukemia) Mouroge H. Al-Ani Jaffer M. Al-Gabban, CABP CABP Suzan Mahmood MD Background: Acute propmylocytic leukemia APL is a subgroup
More informationAcute Promyelocyte Leukemia in A Child Presented With Proptosis: A Case Report And Literature Review
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. V (June. 2017), PP 29-33 www.iosrjournals.org Acute Promyelocyte Leukemia in A Child
More informationAcute Leukemias. haematologica 2001; 86:
Acute Leukemias The PML-RARα transcript in long-term follow-up of acute promyelocytic leukemia patients original paper haematologica 2001; 86:577-585 http://www.haematologica.it/2001_06/0577.htm PAULA
More informationDisclosures of Massimo Breccia
Disclosures of Massimo Breccia Company name Research support Employee Consultant Stockholder Speakers bureau Advisory board Other Novar
More informationAcute promyelocytic leukemia
Open access, freely available online Research in Translation Retinoic Acid and Arsenic for Treating Acute Promyelocytic Leukemia Guang-Biao Zhou, Wei-Li Zhao, Zhen-Yi Wang, Sai-Juan Chen, Zhu Chen* Acute
More informationUnique treatment cures once deadly cancer
THE SJÖBERG PRIZE 2018 POPULAR SCIENCE BACKGROUND Unique treatment cures once deadly cancer The recipients of the Sjöberg Prize 2018, Zhu Chen, Anne Dejean and Hugues de Thé, have clarified molecular mechanisms
More informationAcute Promyelocytic Leukemia
Acute Promyelocytic Leukemia Outline of Management Suleimman AlSweedan,MD,MS,FAAP Consultant Pediatric Hematology/oncology TABLE OF CONTENTS Background 3 Pediatric APL Trials 4 Adult APL Trials 4 Diagnostic
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_acute_myeloid_leukemia
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationAcute Promyelocytic Leukemia: A History over 60 Years From the Most Malignant to the most Curable Form of Acute Leukemia
https://doi.org/10.1007/s40487-018-0091-5 REVIEW Acute Promyelocytic Leukemia: A History over 60 Years From the Most Malignant to the most Curable Form of Acute Leukemia Xavier Thomas Received: August
More informationPETHEMA; 2 HOVON; 3 PLAG and 4 GATLA Groups.
Clinical significance of complex karyotype at diagnosis in Pa7ents with Acute Promyelocy7c Leukemia Treated with ATRA and chemotherapy based PETHEMA trials Labrador J 1, Montesinos P 1, Bernal T 1, Vellenga
More informationMolecular Remission Induction with Retinoic Acid and Anti-CD33 Monoclonal Antibody HuM195 in Acute Promyelocytic Leukemia 1
372 Vol. 6, 372 380, February 2000 Clinical Cancer Research Molecular Remission Induction with Retinoic Acid and Anti-CD33 Monoclonal Antibody HuM195 in Acute Promyelocytic Leukemia 1 Joseph G. Jurcic,
More informationStories. Poisoning the Devil
Leading Edge Stories Poisoning the Devil Zhu Chen and Sai-Juan Chen Our sight was caught by the subject line of an email we received on March 12, 2016: American Society of Hematology (ASH) Ernest Beutler
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationArsenic Trioxide: An Emerging Therapy for Multiple Myeloma
Arsenic Trioxide: An Emerging Therapy for Multiple Myeloma NIKHIL C. MUNSHI University of Arkansas for Medical Science, Little Rock, Arkansas, USA Key Words. Arsenic trioxide Multiple myeloma Antiangiogenesis
More informationDone By : WESSEN ADNAN BUTHAINAH AL-MASAEED
Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED Acute Myeloid Leukemia Firstly we ll start with this introduction then enter the title of the lecture, so be ready and let s begin by the name of Allah : We
More informationTHE LEUKEMIAS. Etiology:
The Leukemias THE LEUKEMIAS Definition 1: malignant transformation of the pluripotent stem cell, successive expansion of the malignant clone from the bone marrow to the tissues Definition 2: Heterogenous
More informationManagement of Relapsed APL
THE INAUGURAL ASEAN FEDERATION OF HAEMATOLOGY SCIENTIFIC MEETING AND THE VIIITH MALAYSIAN NATIONAL HAEMATOLOGY SCIENTIFIC MEETING - SHANGRILA HOTEL KUALA LUMPUR, 22-24 APRIL 2010 Management of Relapsed
More informationMolecular Targets of Arsenic Trioxide in Malignant Cells
Molecular Targets of Arsenic Trioxide in Malignant Cells WILSON H. MILLER, JR. Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital and McGill University Departments
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1998, by the Massachusetts Medical Society VOLUME 339 N OVEMBER 5, 1998 NUMBER 19 COMPLETE REMISSION AFTER TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationInfluence of initiation time and white blood cell count on the efficacy of cytotoxic agents in acute promyelocytic leukemia during induction treatment
BIOMEDICAL REPORTS 9: 227-232, 2018 Influence of initiation time and white blood cell count on the efficacy of cytotoxic agents in acute promyelocytic leukemia during induction treatment FANG XU 1, CHANG-XIN
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Recall the dose-limiting toxicity and preliminary clinical response results with 14- and 21-day extended treatment schedules of daily oral azacitidine. Apply new research
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationELIGIBILITY: Newly diagnosed acute promyelocytic leukemia (APL) with low to intermediate risk (WBC less than 10 x 10 9 /L)
BCCA Protocol Summary for First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide and Tretinoin (All-Trans Retinoic Acid) Protocol Code Tumour Group Contact
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationELIGIBILITY: Newly diagnosed acute promyelocytic leukemia (APL) with high risk (WBC more than 10 x 10 9 /L)
BC Cancer Protocol Summary for First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide, Tretinoin (All-Trans Retinoic Acid) and DAUNOrubicin Protocol Code
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationIntroduction CLINICAL TRIALS AND OBSERVATIONS
CLINICAL TRIALS AND OBSERVATIONS Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and
More informationTargeting of leukemia-initiating cells in acute promyelocytic leukemia
Review Article Page 1 of 8 Targeting of leukemia-initiating cells in acute promyelocytic leukemia Ugo Testa 1, Francesco Lo-Coco 2 1 Department of Hematology, Oncology and Molecular Medicine, Istituto
More informationTARGETED THERAPY FOR CHILDHOOD CANCERS
TARGETED THERAPY FOR CHILDHOOD CANCERS AZIZA SHAD, MD AMEY DISTINGUISHED PROFESSOR OF PEDIATRIC HEMATOLOGY ONCOLOGY, BLOOD AND MARROW TRANSPLANTATION LOMBARDI CANCER CENTER GEORGETOWN UNIVERSITY HOSPITAL
More informationCurrent standard treatment of adult acute promyelocytic leukaemia
review Current standard treatment of adult acute promyelocytic leukaemia Francesco Lo-Coco, 1,2 Laura Cicconi 1,2 and Massimo Breccia 3 1 Department of Biomedicine and Prevention, Tor Vergata University,
More informationWBCs Disorders 1. Dr. Nabila Hamdi MD, PhD
WBCs Disorders 1 Dr. Nabila Hamdi MD, PhD ILOs Compare and contrast ALL, AML, CLL, CML in terms of age distribution, cytogenetics, morphology, immunophenotyping, laboratory diagnosis clinical features
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationThe tenth acute myeloid leukemia (AML) trial conducted
CLINICL UPDTE U p d a t e s o n s t u d y f i n d i n g s i n e s s e n t i a l t h e r a p e u t i c a r e a s o f c a n c e r a n d b l o o d d i s o r d e r s Long-term Results of the MRC ML1 Trial
More informationProgress in the treatment of acute promyelocytic leukemia. Lionel Adès, MD PhD Hopital Saint Louis, Paris Diderot University
Progress in the treatment of acute promyelocytic leukemia Lionel Adès, MD PhD Hopital Saint Louis, Paris Diderot University 대한혈액학회 Korean Society of Hematology COI disclosure Name of author : Lionel Adès
More informationStem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience -
Stem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience - R E S E A R C H A S S O C I A T E P R O F. D - R Z L A T E S T O J A N O S K I Definition Acute myeloid
More informationArsenic Trioxide Selectively Induces Apoptosis within the Leukemic Cells of APL Patients with t(15;17) Translocation Possibly through the Fas Pathway
Arsenic Trioxide Selectively Induces Apoptosis within the Leukemic Cells of APL Patients with t(15;17) Translocation Possibly through the Fas Pathway Ardjmand. A.R. 1, Alimoghaddam. K. 2, Zaker F. 3, Ghavamzadeh
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091534 Age 36 Years Gender Female 1/9/2017 120000AM 1/9/2017 105316AM 2/9/2017 104147AM Ref By Final LEUKEMIA GENETIC ROFILE ANY SIX MARKERS, CR QUALITATIVE AML ETO
More informationDownregulation of the c-myc target gene, peroxiredoxin III, contributes to Arsenic Trioxide-induced apoptosis in Acute Promyelocytic Leukemia (APL)
Downregulation of the c-myc target gene, peroxiredoxin III, contributes to Arsenic Trioxide-induced apoptosis in Acute Promyelocytic Leukemia (APL) Pablo E. Vivas-Mejía, Ph.D. Research Scientist, University
More informationTamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia: Results From a Randomized Controlled Trial
VOLUME 32 NUMBER 33 NOVEMBER 20 2014 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia: Results From a Randomized Controlled
More informationImprovements with Risk-adapted PETHEMA Protocols in New Diagnosed Acute Promyelocytic Leukemia
Improvements with Risk-adapted PETHEMA Protocols in New Diagnosed Acute Promyelocytic Leukemia Miguel A. Sanz Chairman, Spanish PETHEMA Group University Hospital La Fe Valencia, Spain 7 th International
More informationCD34 + therapy-related acute promyelocytic leukemia in a patient previously treated for breast cancer
Case Report Page 1 of 5 CD34 + therapy-related acute promyelocytic leukemia in a patient previously treated for breast cancer John Savooji 1, Fouzia Shakil 1,2, Humayun Islam 1,2, Delong Liu 1, Karen Seiter
More informationCharles Mxxx DCEM2 Toulouse Purpan Medical School 01/26/2012 ECN Item 162
Charles Mxxx DCEM2 Toulouse Purpan Medical School 01/26/2012 ECN Item 162 Definition Pathophysiology Clinical signs and symptoms Biology and Diagnosis Different types of AL Prognosis and Treatment Malignant
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_cll_and_sll 2/2001
More informationJohann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD
Photo by Tynan Studio Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD 96 Atlas of Childhood Cancer in Ontario (1985-2004) Chapter 6: Leukemia 6 Leukemia Atlas of Childhood
More information4 th International Symposium, Rome, Italy, September 29 - October 1, 2005
CORPORATE SYMPOSIUM STRATEGIES FOR ADVANCED APL: LONG-TERM FOLLOWUP OF ARSENCE THERAPY AND NEW APPROACHES Tallman MS Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationFluorescence in-situ Hybridization (FISH) ETO(RUNX1T1)/AML1(RUNX1) or t(8;21)(q21.3;q22)
PML/RARA t(15;17) Translocation Assay Result : nuc ish(pml 2)(RARA 2)[200] : 200/200(100%) interphase nuclei show normal 2O 2G signals for PML/RARA : is Negative for t(15;17)(q22;q21.1) 2 Orange 2 Green
More informationMedical Policy. MP Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Medical Policy MP 8.01.26 BCBSA Ref. Policy: 8.01.26 Last Review: 01/30/2018 Effective Date: 01/30/2018 Section: Therapy Related Policies 2.04.124 Genetic Testing for FLT3, NPM1, and CEBPA Variants in
More informationFirst Reported Case of Aplastic Anemia Occurring in a Patient after Acute Promyelocytic Leukemia in Remission
H&0 CLINICAL CASE STUDIES First Reported Case of Aplastic Anemia Occurring in a Patient after Acute Promyelocytic Leukemia in Remission Alexander Pham, MD 1 Bahareh Bahadini, MD 2 Randa Alsabeh, MD 3 Amir
More information